IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models – with a strong cardiovascular focus. At IPST we believe each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated. We believe in taking ownership of the studies entrusted to IPST while ensuring mutual collaboration for developing and agreeing to overall project plans. Established in 1999, we have conducted more than 600 preclinical cardiac safety and efficacy studies and over 100 GLP-compliant studies in support of FDA, EMEA, Health Canada and MoHW. In 2014, IPST completed a major expansion of our laboratory and research office facility – increasing our capacity to get the right data the first time. Every time.